- In February 2024, Roche entered into collaboration agreement with PathAI to expand digital pathology capabilities for companion diagnostics. The collaboration provides Roche with PathAI’s advanced AI technology for improving companion diagnostics. It ensures exclusive, tailored solutions and accelerates algorithm development while allowing Roche to continue developing its own diagnostics
- In July 2024, Roche announced the successful acquisition of LumiraDx’s Point of Care technology, following the necessary antitrust and regulatory approvals. This integration enhanced Roche’s diagnostics portfolio with a user-friendly platform that consolidates various immunoassay and clinical chemistry tests. The acquisition aimed to improve access to diagnostic testing, particularly in primary care and underserved regions, aligning with Roche's commitment to decentralised healthcare solutions
- In July 2023, Bio-Rad and QIAGEN have announced a patent settlement and cross-licensing agreement that resolves ongoing disputes regarding specific technologies. This partnership allows both companies to enhance their product portfolios and accelerate innovation in the life sciences sector, ultimately benefiting their customers by providing broader access to advanced technologies and improved solutions in research and diagnostics
- In May 2023, Thermo Fisher and BRIN have partnered to enhance research capabilities in Indonesia, focusing on advancing scientific innovation and collaboration in life sciences, biotechnology, and environmental studies for local researchers
